Recent studies have provided a critical assessment of the therapeutic options in diabetes and obesity and highlighted the various approaches used to date, including (a) antidiabetics, (b) incretin and glucagon like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase inhibitors, (c) lifestyle modifications, (d) antiobesity agents, and (e) bariatric surgery [1, 19]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.